Inhibrx Biosciences, Inc.
ozekibart (INBRX-109)
colorectal cancer
Resolved
6days ago
Advisory committee · Jul 1, 2026
What's at stake
An FDA advisory committee reviews ozekibart (INBRX-109) for colorectal cancer around Jul 1, 2026. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 13h ago
“We also plan to discuss with the FDA the potential for accelerated regulatory pathways for ozekibart in fourth-line colorectal cancer and in refractory Ewing sarcoma.”